GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (NAS:MRKR) » Definitions » Total Current Liabilities

Marker Therapeutics (Marker Therapeutics) Total Current Liabilities : $2.30 Mil (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Marker Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Marker Therapeutics's total current liabilities for the quarter that ended in Mar. 2024 was $2.30

Marker Therapeutics Total Current Liabilities Historical Data

The historical data trend for Marker Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Total Current Liabilities Chart

Marker Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.99 6.40 12.90 7.78 3.08

Marker Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 2.92 2.78 3.08 2.30

Marker Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Marker Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.348+0
+Other Current Liabilities+Current Deferred Liabilities
=-1.273+0
=3.08

Marker Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.304+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Marker Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics (Marker Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (NAS:MRKR) » Definitions » Total Current Liabilities
Comparable Companies
LPCN QNCX CARA FBIO VYNE BCLI ESLA INKT UNCY EYEN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
GX1:Germany
Address
4551 Kennedy Commerce Drive, Houston, TX, USA, 77032
Website
http://www.markertherapeutics.com
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Executives
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Frederick Gerald Wasserman director 4 NOBADEER DRIVE, PENNINGTON NJ 08534
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Peter L. Hoang director, officer: CEO and President C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Norman David Eansor director 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Juan Vera director 2925 RICHMOND AVENUE, SUITE 1274, HOUSTON TX 77098